What is this study trying to find out about brain metastasis?

This study is investigating whether new imaging methods using PET and MRI can better detect cancerous brain tumors compared to current imaging techniques. The goal is to improve tumor detection to help guide future cancer treatments. The research is sponsored by the University of Wisconsin, Madison.

Who may be eligible for this brain metastasis clinical trial?

Adults aged 18 years or older with a diagnosis of brain metastasis and at least one visible tumor on MRI may be eligible. Participants should have received radiation therapy in the last 2 years and have recent systemic treatments like immunotherapy or chemotherapy. This study accepts all genders. Please review eligibility criteria for more details.

Is there any cost to participate in this brain metastasis clinical trial?

Study-related care, including the PET/MRI scans and all trial visits, is provided at no cost. However, personal travel and accommodation expenses may vary and are not guaranteed to be covered by the study.

Actively Recruiting

Phase 3

Age: 18Years +

All Genders

ID06159335

Use of 18F-Fluciclovine PET to Identify Tumors in Patients With Brain Metastases Receiving Immunotherapy

Led by University of Wisconsin, Madison · Updated on 2026-02-03

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating new imaging techniques to better detect tumors in people with brain metastasis. This study focuses on comparing positron emission tomography PET combined with magnetic resonance imaging MRI against other imaging methods to determine if these newer techniques can more accurately identify cancerous tissue. Improved imaging is important to help locate tumors and guide future cancer treatments. Participants will undergo a single PETMRI scan using a radiotracer called F-Fluciclovine, followed by a separate MRI scan with a tracer. These imaging methods are performed on the same machine that creates detailed pictures using magnets and radio waves. The PET and MRI scans assess protein levels in tumor tissue, with higher protein levels suggesting tumor presence rather than normal brain tissue. During the study visit, which lasts about three hours, participants will be asked to lie still for 30 to 60 minutes during imaging. Researchers will measure amino acid uptake into tumor tissue to compare imaging results. Patients must be able to complete the scans without requiring intravenous sedation, and medication use for mild anxiety is allowed under specific conditions. All scans and procedures are conducted to monitor tumor presence and treatment changes safely.

CONDITIONS

Brief Title

18F-FLUC PET/MR in Patients With Brain Mets

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 years or older
Able and willing to provide informed consent
Diagnosed with brain metastasis with at least one visible tumor lesion on brain MRI
Received radiation therapy within the past 2 years
Currently or recently (within 6 months) treated with systemic therapy such as immunotherapy, targeted therapy, or chemotherapy
Recent MRI suggests possible tumor recurrence versus treatment effects
Able to lie still for 30 to 60 minutes during imaging
Willing and able to undergo PET/MRI or PET/CT imaging
If using oral anxiety medication for imaging, must have own prescription, consent prior to use, and come with a driver

You will not qualify if you...

Unable or unwilling to provide informed consent
Pregnant
Contraindications to PET/MR or PET/CT imaging
Known allergy to 18F-Fluciclovine or any of its components

Research Team

Radiology Studies

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here